A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer
Susana M. Campos,Oday Hamid,Michael V. Seiden,Amit M. Oza,Marie Plante,Ronald K. Potkul,Peter F. Lenehan,Eric Kaldjian,Mary Varterasian,Cheryl Jordan,Claudie Charbonneau,Hal W. Hirte +11 more
TL;DR: There appears to be no association between baseline erbB expression and disease stability in unscreened patients with advanced ovarian cancer, and CI-1033 had a more favorable adverse events profile than at 200 mg/d.
Journal ArticleDOI
VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study
William P. Tew,Nicoletta Colombo,I.L. Ray-Coquard,Amit M. Oza,J. M. Del Campo,Giovanni Scambia,David R. Spriggs +6 more
TL;DR: This is a randomized, double blind, multicenter, 2-stage, phase II trial of VEGF Trap, a potent angiogenesis inhibitor fusion protein, comprised of portions of human V EGF-receptor R1+R2 extracellular domains and fused to the Fc portion of human IgG.
Journal Article
Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
M. Christine Cripps,Alvaro T. Figueredo,Amit M. Oza,Marianne Taylor,Anthony L. Fields,John T. Holmlund,L. McIntosh,Richard S. Geary,Elizabeth Eisenhauer +8 more
TL;DR: Neither ISIS 5132 nor ISIS 3521 given in the dose and schedule studied induced objective responses in untreated colorectal cancer patients.
Journal ArticleDOI
A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184.
Helen Mackay,Anna V. Tinker,Eric Winquist,Gillian Thomas,Kenneth D. Swenerton,Amit M. Oza,Joana Sederias,Percy Ivy,Elizabeth Eisenhauer +8 more
TL;DR: Sunitinib has insufficient activity as a single agent in cervical cancer to warrant further investigation and is of concern.
Journal ArticleDOI
Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.
Karen A. Gelmon,Hal W. Hirte,André Robidoux,Katia Tonkin,Marc Tischkowitz,Kenneth D. Swenerton,David Huntsman,James Carmichael,Euan Macpherson,Amit M. Oza +9 more
TL;DR: A phase II translational study evaluating tumor response with serial tumor biopsies to determine markers of response in BRCA mutation carriers and Olaparib is a PARP inhibitor (PARPi) which has reported encouraging response data in BRA mutation carriers.